Introduction
Primary malignant cardiac tumours are rare (incidence <0.005%) and often present due to symptoms from local mass effect. Common symptoms include dyspnoea, chest pain, and congestive heart failure secondary to compromised blood flow 1 ; these symptoms are nonspecific and often mimic other conditions i.e. acute pulmonary embolism. Despite surgical resection and chemotherapy prognosis remains poor with a median survival of 6-12 months. We report the use of tumour genome sequencing to allow for personalized treatment to optimize outcomes.
Timeline Case summary
An 18-year-old female patient with no prior medical history presented to the emergency department with a one month history of fatigue and lethargy without associated constitutional symptoms of weight loss or fevers. She complained of pre-syncope and severe dyspnoea on minimal exertion (a single flight of stairs) culminating in paroxysmal nocturnal dyspnoea associated, chest tightness and palpitations which acutely precipitated her presentation. She was a non-smoker with no relevant family history.
On presentation the patient was afebrile, but had an elevated respiratory rate of 22 breaths/minute with an oxygen saturation of 98% without supplemental oxygen. She had a sinus tachycardia of 140 b.p.m., was normotensive with no postural deficit (120/ 80 mmHg lying and 118/82 mmHg standing). Examination revealed no peripheral oedema and a non-elevated jugular venous pressure. Cardiac auscultation revealed a II/VI pan-diastolic murmur with no additional sounds and no right ventricular heave. The chest was resonant to percussion, but breath sounds were decreased bibasally.
Laboratory results revelled a d-dimer of 6.6 lg/mL (<0.5 lg/mL) and a haemoglobin of 13.7 g/dL (12.3-15.3 g/dL); the remainder of the blood count and biochemistry being within normal limits. An ECG revealed sinus tachycardia with normal p-wave axis (þ60 ) and a narrow QRS. A chest X-ray demonstrated mild blunting of the costophrenic angles bilaterally. The primary differential diagnosis was a pulmonary embolus (PE) and as such a computed tomography pulmonary angiogram (CTPA) was performed and ruled out a PE, but did demonstrate bilateral pleural effusions and a large (60 Â 38 mm) filling defect in the left atrium ( Figure 1 ). Transthoracic echocardiogram confirmed the presence of a mobile large left atrial mass originating from the intra-atrial septum with associated compromise of the mitral inflow (Supplementary material online, Video S1), there was no associated pericardial effusion. The mass was non-pedunculated and partially prolapsed into the LV during diastole with anterior displacement of the anterior mitral valve leaflet. There was no thrombus in association with the mass; however, anticoagulation was commenced with a heparin infusion. A full-body CT scan revealed no evidence of distant metastasis. A left atrial mass arising from the intraatrial septum is most commonly a benign atrial myxoma, but the differential includes thrombus and a wide variety of primary and secondary malignant tumours. Due to the compromise of the mitral inflow and cardiovascular compromise as indicated by the presence of a significant sinus tachycardia urgent cardiothoracic surgery was performed to resect the tumour ( Figure 2) . Intra-operatively the mitral valve was found to be structurally intact and did not need repair or replacement and the tumour was successfully resected (Figure 3) . Histological analysis identified the tumour as an undifferentiated pleomorphic sarcoma and chemotherapy with doxorubicin and ifosfamide was administered over a period of 18 weeks (six cycles of doxorubicin (25 mg/m 2 intravenously) on Days 1-3, ifosfamide (2.5 g/m 2 intravenously) on Days 1-4 and pegylated granulocyte colony stimulating factor (6 mg subcutaneously) on Day 5. Each cycle consists of 21 days). The patient was initially followed up with three monthly cardiac magnetic resonance imaging (cMRI), CT, and transoesophageal echocardiogram for 24 months and then with six monthly cMRI scans planned until 60 months post-surgery. Additionally, we performed comprehensive tumour genome sequencing to identify cancer-driving mutations and to enable personalized, targeted therapy against molecular and genetic factors promoting tumour growth. This analysis revealed amplification of 12q including cyclin-dependent kinase 4 (CDK-4) and thereby identified a viable second line, tumour-specific treatment option, the CDK-4 inhibitor Palbociclib. In this case first-line chemotherapy was effective and Palbociclib was not required, but remains a viable option in the case of recurrence. The patient was able to be discharged 10 days after surgery and remains disease free and asymptomatic at 30 months after surgery with no ongoing therapy. The patient tolerated chemotherapy well with no lasting side effects. 
Discussion
Cardiac tumours often present with non-specific symptoms due to their mass effect, such as dyspnoea, tachycardia, congestive cardiac failure or syncope. They can therefore mimic a variety of other clinical entities such as PE, ischaemic heart disease, cardiac failure, or stroke. Due to their non-specific presentation they are often identified during investigation for other causes, such as in our case with a CTPA for a PE. Cardiac tumours are benign in 80% of cases, predominantly myxomas. 1 It is difficult to differentiate between tumour types non-invasively; cMRI can provide information such as tissue characterization, extent of cardiac, and extracardiac involvement, but the diagnostic accuracy remains low, 68%, compared to the gold standard of histopathological examination. 2 In our case the patient's tachycardia and dyspnoea would have limited cMRI image quality and thus surgical resection was performed to relieve the cardiovascular compromise and to facilitate histological and genetic analysis. Primary cardiac sarcomas account for the majority of primary cardiac malignancies and have a poor prognosis with a median survival of 9 months. 3 First-line treatment consists of surgical resection and chemotherapy with doxorubicin and ifosfamide, 4,5 due to the low incidence of primary cardiac sarcomas this recommendation is based on case reports and retrospective analyses not randomized controlled studies. As with other solid tumours genetic tumour profiling can be performed to help identify alternative therapeutic options including tyrosine kinase inhibitors, monoclonal anti-bodies and, as in our case, CKD-4 inhibitors. Palbociclib is a CDK-4 inhibitor that is currently licenced for hormone receptor positive, human epidermal growth receptor 2 negative breast cancer. There is also phase II trial evidence for its use in liposarcomas which exhibit abnormal amplification of CDK-4 (6) . Its efficacy of CDK-4 inhibition is inversely related to levels of p16ink4 mRNA levels on immunohistochemical analysis. 7 Palbociclib is an oral agent administered over a 28 day cycle; 125 mg daily for 21 days followed by 7 days off. 6 The number of cycles is based on response and is determined on an individual basis. The most common side effects include neutropenia (Grade 3: 56.1%), anaemia (Grade 3: 5.2%), asthenia (Grade 3: 2.3%), and thrombocytopenia (Grade 3: 1.4%) with febrile neutropenia occurring in 3% of patients. 8 
Conclusions
This case highlights the use of tumour genomic sequencing to identify viable second line therapies in cardiac sarcomas. However, reimbursement of such orphan drugs often represents an obstacle to personalized therapy in most health care systems.
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